VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 102,200 shares, a growth of 23.7% from the October 31st total of 82,600 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily trading volume, of 77,300 shares, the days-to-cover ratio is presently 1.3 days.

Wall Street Analyst Weigh In

VYNE has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $5.75 target price on shares of VYNE Therapeutics in a research note on Friday, November 8th. BTIG Research started coverage on shares of VYNE Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $8.00 price objective for the company.

VYNE Therapeutics Trading Up 0.3 %

VYNE stock opened at $2.96 on Monday. The stock’s 50 day simple moving average is $2.48 and its 200 day simple moving average is $2.20. VYNE Therapeutics has a 12-month low of $1.57 and a 12-month high of $3.66. The stock has a market capitalization of $43.66 million, a PE ratio of -3.44 and a beta of 1.32.

Hedge Funds Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,199 shares of the company’s stock, valued at approximately $50,000. Virtu Financial LLC owned 0.11% of VYNE Therapeutics as of its most recent SEC filing. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.